GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orient Pharma Co Ltd (ROCO:4166) » Definitions » Earnings per Share (Diluted)

Orient Pharma Co (ROCO:4166) Earnings per Share (Diluted) : NT$0.48 (TTM As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Orient Pharma Co Earnings per Share (Diluted)?

Orient Pharma Co's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was NT$0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.48.

Orient Pharma Co's EPS (Basic) for the six months ended in Dec. 2024 was NT$0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.48.

Orient Pharma Co's EPS without NRI for the six months ended in Dec. 2024 was NT$0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.53.

During the past 12 months, Orient Pharma Co's average EPS without NRIGrowth Rate was 358.30% per year.

During the past 13 years, Orient Pharma Co's highest 3-Year average EPS without NRI Growth Rate was 50.80% per year. The lowest was -31.50% per year. And the median was 5.25% per year.


Orient Pharma Co Earnings per Share (Diluted) Historical Data

The historical data trend for Orient Pharma Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orient Pharma Co Earnings per Share (Diluted) Chart

Orient Pharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.01 -0.55 -0.15 0.10 0.48

Orient Pharma Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 - 0.10 0.43 0.05

Competitive Comparison of Orient Pharma Co's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Pharma Co's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's PE Ratio falls into.


;
;

Orient Pharma Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Orient Pharma Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(107.374-0)/223.035
=0.48

Orient Pharma Co's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(10.363-0)/223.035
=0.05

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Orient Pharma Co  (ROCO:4166) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Orient Pharma Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Orient Pharma Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Orient Pharma Co Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The company uses its platform technologies for the development of specialty pharmaceutical products and is capable of manufacturing products under cGMP. It provides drugs for treating Alzheimer's disease, psychostimulants, and treating Parkinson's disease.

Orient Pharma Co Headlines

No Headlines